Mesoporous particle-based microcontainers for intranasal delivery of imidazopyridine drugs
Marchenko I., Borodina T. N., Trushina D. B., Rassokhina I., Volkova Y., Shirinian V., Zavarzin I., Gogin A., Bukreeva T.
Journal of Microencapsulation
Vol.35, Issue7-8, P. 657-666
Опубликовано: 2018
Тип ресурса: Статья
DOI:10.1080/02652048.2019.1571642
Аннотация:
The aim of this study was to develop mesoporous containers for entrapment of imidazopyridines, such as sedative–hypnotic medicine zolpidem, anxiolytic agent alpidem and their derivatives. For this purpose, calcium carbonate (size 1.2 µm (PDI: 0.6), zeta potential: −10 mV), manganese carbonate (2.5 µm (PDI: 0.5), zeta potential: −12 mV) and titanium dioxide particles (3.7 µm (PDI: 0.4), zeta potential: −15 mV) were used. The compounds were encapsulated applying two techniques: adsorption on the preformed particles and co-precipitation during the synthesis of the particles. The polymer shell of the containers was formed by electrostatic adsorption of polyelectrolytes on the surface of the particles. The best encapsulation efficacy was shown for zolpidem incorporated into calcium carbonate (5.4[%]) and manganese carbonate (4.6[%]) by adsorption. Release of the compounds from the containers based on the proposed particles were characterised by the short time burst effect (<10 min) followed by
Ключевые слова:
drug delivery; imidazopyridines; intranasal delivery; Mesoporous particles; microcontainers
2 [6 methyl 2 (4 methylphenyl)imidazo[1,2 alpha]pyridin 3 yl]acetic acid; alpidem; calcium carbonate; carbonic acid derivative; imidazopyridine derivative; manganese carbonate; polyelectrolyte; potassium 2 [6 methyl 2 (4 methylphenyl)imidazo[1,2 alpha]pyridin 3 yl]acetate; titanium dioxide; unclassified drug; zolpidem; alpidem; anxiolytic agent; carbonic acid; drug carrier; hypnotic sedative agent; imidazole derivative; imidazopyridine derivative; manganese; pyridine derivative; titanium; zolpidem; animal experiment; Article; controlled study; drug adsorption; drug structure; male; mouse; mucoadhesion; nanoencapsulation; nonhuman; precipitation; retention time; static electricity; zeta potential; adsorption; animal; chemistry; drug release; human; intranasal drug administration; metabolism; nose cavity; particle size; porosity; Administration, Intranasal; Adsorption; Animals; Anti-Anxiety Agents; Calcium Carbonate; Carbonates; Drug Carriers; Drug Liberation; Humans; Hypnotics and Sedat
Язык текста: Английский
ISSN: 1464-5246
Marchenko I.
Borodina T. N. Tat`yana Nikolaevna 1982-
Trushina D. B. Dar`ya Borisovna 1989-
Rassokhina I.
Volkova Y.
Shirinian V.
Zavarzin I.
Gogin A.
Bukreeva T.
Марченко И.
Бородина Т. Н. Татьяна Николаевна 1982-
Трушина Д. Б. Дарья Борисовна 1989-
Рассохина И.
Волкова Y.
Шириниан В.
Заварзин И.
Гогин А.
Букреева Т.
Mesoporous particle-based microcontainers for intranasal delivery of imidazopyridine drugs
Текст визуальный непосредственный
Journal of Microencapsulation
Taylor & Francis Group
Vol.35, Issue7-8 P. 657-666
2018
Статья
drug delivery imidazopyridines intranasal delivery Mesoporous particles microcontainers
2 [6 methyl 2 (4 methylphenyl)imidazo[1,2 alpha]pyridin 3 yl]acetic acid alpidem calcium carbonate carbonic acid derivative imidazopyridine derivative manganese carbonate polyelectrolyte potassium 2 [6 methyl 2 (4 methylphenyl)imidazo[1,2 alpha]pyridin 3 yl]acetate titanium dioxide unclassified drug zolpidem alpidem anxiolytic agent carbonic acid drug carrier hypnotic sedative agent imidazole derivative imidazopyridine derivative manganese pyridine derivative titanium zolpidem animal experiment Article controlled study drug adsorption drug structure male mouse mucoadhesion nanoencapsulation nonhuman precipitation retention time static electricity zeta potential adsorption animal chemistry drug release human intranasal drug administration metabolism nose cavity particle size porosity Administration, Intranasal Adsorption Animals Anti-Anxiety Agents Calcium Carbonate Carbonates Drug Carriers Drug Liberation Humans Hypnotics and Sedat
The aim of this study was to develop mesoporous containers for entrapment of imidazopyridines, such as sedative–hypnotic medicine zolpidem, anxiolytic agent alpidem and their derivatives. For this purpose, calcium carbonate (size 1.2 µm (PDI: 0.6), zeta potential: −10 mV), manganese carbonate (2.5 µm (PDI: 0.5), zeta potential: −12 mV) and titanium dioxide particles (3.7 µm (PDI: 0.4), zeta potential: −15 mV) were used. The compounds were encapsulated applying two techniques: adsorption on the preformed particles and co-precipitation during the synthesis of the particles. The polymer shell of the containers was formed by electrostatic adsorption of polyelectrolytes on the surface of the particles. The best encapsulation efficacy was shown for zolpidem incorporated into calcium carbonate (5.4[%]) and manganese carbonate (4.6[%]) by adsorption. Release of the compounds from the containers based on the proposed particles were characterised by the short time burst effect (<10 min) followed by